Display options
Cite
Watkins G, Douglas-Jones A, Mansel RE, et al. Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. Int Semin Surg Oncol. 2005;2:23doi: 10.1186/1477-7800-2-23.
Watkins, G., Douglas-Jones, A., Mansel, R. E., & Jiang, W. G. (2005). Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. International seminars in surgical oncology : ISSO, 223. https://doi.org/10.1186/1477-7800-2-23
Watkins, Gareth, et al. "Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer." International seminars in surgical oncology : ISSO vol. 2 (2005): 23. doi: https://doi.org/10.1186/1477-7800-2-23
Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. Int Semin Surg Oncol. 2005 Oct 26;2:23. doi: 10.1186/1477-7800-2-23. PMID: 16250911; PMCID: PMC1289289.
Copy Download .nbib Format: NLM
Share it on

Int Semin Surg Oncol. 2005 Oct 26;2:23. doi: 10.1186/1477-7800-2-23.

Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer.

International seminars in surgical oncology : ISSO

Gareth Watkins, Anthony Douglas-Jones, Robert E Mansel, Wen G Jiang

Affiliations

  1. Metastasis & Angiogenesis Research Group, Wales College of Medicine, Cardiff University, Cardiff, UK. [email protected]

PMID: 16250911 PMCID: PMC1289289 DOI: 10.1186/1477-7800-2-23

Abstract

BACKGROUND: Thromboxane synthase (TxS) metabolizes the cyclooxygenase product, prostaglandin H(2), into thromboxanes. Some of the thromboxanes are known to be biologically active on cancer cells. The aim of the study was to investigate the expression of thromboxane synthases, TBXAS1 and the thromboxane A2 receptor, TBXA2R in a cohort of human breast cancer patients and also to assess their potential clinical relevance.

METHODS: Human breast tumour tissues (n = 120) and non-neoplastic mammary tissues (n = 32) were studied. Levels of TBXA2R and TBXAS1 transcripts were quantified using quantitative real-time RT-PCR analysis and correlated with clinical/pathological information including nodal status, grade, prognosis and long term survival (median follow-up period 120 months).

RESULTS: Breast tumour tissue expressed higher levels of TBXA2R compared with normal mammary tissues, although the difference was not statistically significant (p = 0.09). There was no difference between tumour and normal tissues for TBXAS1. However, TBXA2R expression was significantly increased in grade 3 tumours(p = 0.006 vs grade 1), while TBXAS1 was significantly reduced in grade 3 tumours (p = 0.026 vs grade 1 tumours). A similar differential expression pattern was seen in tumours from patients with different prognosis, in that patients with predicted poor prognosis had higher, but not statistically different, levels of TBXA2R, and significantly lower levels of TBXAS1 (p = 0.008). Finally, Kaplan-Meier survival analysis has shown that patients with high levels of TBXA2R had significantly shorter disease free survival (103.8 (79.1-128.5) months) compared with those with low levels (123.7 (112.0-135.3)) months, p = 0.043.

CONCLUSION: Thromboxane synthases are differentially expressed in human breast cancer. While TBXA2R is highly expressed in aggressive tumours and linked with poor prognosis, TBXAS1 is expressed at significantly low levels in high grade tumours and tumour patients with poor prognosis. TBXA2R thus has a significant prognostic value in clinical breast cancer.

References

  1. Biochem Biophys Res Commun. 2000 Jan 7;267(1):245-51 - PubMed
  2. J Cancer Res Clin Oncol. 2001 Dec;127(12):751-4 - PubMed
  3. Clin Cancer Res. 2003 Dec 15;9(17):6432-40 - PubMed
  4. Biochem J. 1996 Nov 1;319 ( Pt 3):783-91 - PubMed
  5. Endocrinology. 1996 Dec;137(12):5739-42 - PubMed
  6. Clin Exp Metastasis. 1983 Apr-Jun;1(2):103-14 - PubMed
  7. Cancer Res. 1987 Feb 15;47(4):988-91 - PubMed
  8. Cancer Res. 2000 Mar 15;60(6):1604-8 - PubMed
  9. Int J Cancer. 1987 Apr 15;39(4):488-91 - PubMed
  10. Exp Cell Res. 1994 Sep;214(1):120-30 - PubMed
  11. FEBS Lett. 1992 Jul 20;306(2-3):161-4 - PubMed
  12. Prostaglandins Leukot Essent Fatty Acids. 2005 Apr;72(4):267-72 - PubMed
  13. Res Exp Med (Berl). 1995;195(4):209-15 - PubMed
  14. Acta Oncol. 1994;33(6):708-9 - PubMed
  15. Prostaglandins Leukot Essent Fatty Acids. 2003 Oct;69(4):275-81 - PubMed
  16. Am J Pathol. 2004 Feb;164(2):429-39 - PubMed
  17. Clin Cancer Res. 2003 May;9(5):1604-10 - PubMed
  18. Clin Cancer Res. 2005 Aug 15;11(16):6012-9 - PubMed
  19. Blood. 1991 Dec 15;78(12):3178-85 - PubMed
  20. Prog Lipid Res. 1992;31(2):163-94 - PubMed
  21. Endocr Relat Cancer. 2004 Dec;11(4):781-91 - PubMed
  22. Ann Oncol. 2002 May;13(5):669-78 - PubMed
  23. J Med Chem. 1991 Jan;34(1):267-76 - PubMed
  24. J Biol Chem. 1991 Feb 25;266(6):3888-92 - PubMed
  25. Br J Cancer. 1986 Aug;54(2):257-63 - PubMed
  26. Neuro Oncol. 1999 Jan;1(1):3-13 - PubMed
  27. Cancer Res. 2002 Jan 1;62(1):63-6 - PubMed
  28. J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):487-93 - PubMed
  29. Acta Neurochir (Wien). 2002 Jan;144(1):71-87 - PubMed
  30. J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):41-7 - PubMed
  31. Int J Cancer. 2005 Dec 10;117(5):730-7 - PubMed
  32. Int J Cancer. 2003 Sep 20;106(5):752-7 - PubMed
  33. J Surg Res. 1988 Apr;44(4):425-9 - PubMed
  34. Cancer Biochem Biophys. 1986 Dec;9(1):97-104 - PubMed

Publication Types